ProMIS Neurosciences is trading at $14.76 (up 7.6%) in pre-market action, rebounding from a period of profit-taking and broader biotech sector weakness seen on July 31.
- The upward move appears driven by technical factors and a firmer risk-on tone in U.S. futures rather than a new fundamental catalyst.
- There are currently no fresh company-specific headlines, earnings reports, or regulatory updates tied to the price increase.
- The recovery follows a sharp pullback in the previous session, suggesting a stabilization in investor sentiment.